Skip to main content
. 2019 Feb 9;13(4):909–927. doi: 10.1002/1878-0261.12446

Figure 7.

Figure 7

Clinical implications of the sub‐expression of LncKLHDC7B and KLHDC7B in TNBC. (A) Kaplan–Meier analysis curve of the disease‐free survival (DFS) of TNBC according to KLHDC7B expression. (B) Kaplan–Meier analysis of overall survival (OS) according to KLHDC7B expression. (C) Kaplan–Meier analysis of prognostic relevance of LncKLHDC7B expression from public data. (D) In silico prediction of susceptibility to USFDA‐approved treatment drugs related with LncLHDC7B expression in triple‐negative breast cancer cell line.